Τίτλος:
Pneumococcal vaccination strategies among HIV-infected adult patients: A review of the literature
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: Streptococcus pneumoniae is the leading cause of bacterial pneumonia and an important cause of invasive disease. Despite the antiretroviral therapies, adults infected with human immunodeficiency virus (HIV) are at particular risk for invasive pneumococcal disease (IPD). The purpose of this study was to report the efficacy of the strategies currently being used in pneumococcal vaccination for HIV-infected adults. Materials and Methods: A literature search was performed through electronic databases, for original articles in English, from years 2000 to 2019. Clinical trials controlled or randomized, and cohort studies were included. Results: While 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for immunocompromised patients, it has been reported that it is less suitable for HIV-infected patients. Recent guidelines have added pneumococcal conjugate vaccine (PCV) to the list of recommended vaccines. Conclusion: Further studies are needed to determine the optimal vaccines and intervals for subsequent revaccinations during the lifetime. © 2019 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
Garmpi, A.
Damaskos, C.
Garmpis, N.
Patsouras, A.
Savvanis, S.
Gravvanis, N.
Diamantis, E.
Περιοδικό:
In vivo (Athens, Greece)
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
placebo; Pneumococcus vaccine; 23-valent pneumococcal capsular polysaccharide vaccine; Pneumococcus vaccine, adult; clinical effectiveness; cohort analysis; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; immunocompromised patient; infection prevention; Medline; pneumococcal infection; practice guideline; randomized controlled trial (topic); Review; vaccination; complication; Human immunodeficiency virus infection; immunology; pneumococcal infection; procedures; virology, Heptavalent Pneumococcal Conjugate Vaccine; HIV Infections; Humans; Immunocompromised Host; Pneumococcal Infections; Pneumococcal Vaccines; Vaccination
DOI:
10.21873/invivo.11620
